about
Membrane-bound nitrate reductase is required for anaerobic growth in cystic fibrosis sputumTreatments for preventing recurrence of infection withPseudomonas aeruginosain people with cystic fibrosisThe Evolution of Cystic Fibrosis CareThe role of microbial biofilms in prosthetic joint infectionsInhalable Antimicrobials for Treatment of Bacterial Biofilm-Associated Sinusitis in Cystic Fibrosis Patients: Challenges and Drug Delivery Approaches.Bacterial community morphogenesis is intimately linked to the intracellular redox statePseudomonas aeruginosa biofilms in cystic fibrosisThe AlgT-dependent transcriptional regulator AmrZ (AlgZ) inhibits flagellum biosynthesis in mucoid, nonmotile Pseudomonas aeruginosa cystic fibrosis isolatesPA3297 Counteracts Antimicrobial Effects of Azithromycin in Pseudomonas aeruginosa.Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa in cystic fibrosisThe two peptide lantibiotic lacticin 3147 acts synergistically with polymyxin to inhibit Gram negative bacteria.Quorum sensing and virulence of Pseudomonas aeruginosa during lung infection of cystic fibrosis patientsMeasuring and improving respiratory outcomes in cystic fibrosis lung disease: opportunities and challenges to therapyStructural and antimicrobial properties of human pre-elafin/trappin-2 and derived peptides against Pseudomonas aeruginosa.Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosisTrue microbiota involved in chronic lung infection of cystic fibrosis patients found by culturing and 16S rRNA gene analysis.The microorganisms in chronically infected end-stage and non-end-stage cystic fibrosis patients.Proteomic profiling of Pseudomonas aeruginosa AES-1R, PAO1 and PA14 reveals potential virulence determinants associated with a transmissible cystic fibrosis-associated strainNeurotrophic and neuroimmune responses to early-life Pseudomonas aeruginosa infection in rat lungs.Pharmacokinetics and pharmacodynamics of aerosolized antibacterial agents in chronically infected cystic fibrosis patients.Tolerance to the antimicrobial peptide colistin in Pseudomonas aeruginosa biofilms is linked to metabolically active cells, and depends on the pmr and mexAB-oprM genes.Exhaled breath analysis using electronic nose in cystic fibrosis and primary ciliary dyskinesia patients with chronic pulmonary infections.Acinetobacter baumannii: emergence of a successful pathogenComparable population pharmacokinetics and pharmacodynamic breakpoints of cefpirome in cystic fibrosis patients and healthy volunteers.Proposal of a quantitative PCR-based protocol for an optimal Pseudomonas aeruginosa detection in patients with cystic fibrosis.Is the improvement of CF patients, hospitalized for pulmonary exacerbation, correlated to a decrease in bacterial load?Co-culture models of Pseudomonas aeruginosa biofilms grown on live human airway cells.A case of failed eradication of cystic fibrosis-related sinus colonisation by Pseudomonas aeruginosaBacteriophages φMR299-2 and φNH-4 can eliminate Pseudomonas aeruginosa in the murine lung and on cystic fibrosis lung airway cellsSystematic comparison of the population pharmacokinetics and pharmacodynamics of piperacillin in cystic fibrosis patients and healthy volunteers.Emergence of Pseudomonas aeruginosa cross-infection in children with cystic fibrosis attending an Iranian referral pediatric center.Challenges in Laboratory Detection of Fungal Pathogens in the Airways of Cystic Fibrosis Patients.Identification of a small molecule that simultaneously suppresses virulence and antibiotic resistance of Pseudomonas aeruginosa.Multidrug-resistant organisms in cystic fibrosis: management and infection-control issues.The use of fluoroquinolones in children: recent advances.Risk factors for age at initial Pseudomonas acquisition in the cystic fibrosis epic observational cohort.Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study.Evolving epidemiology of Pseudomonas aeruginosa and the Burkholderia cepacia complex in cystic fibrosis lung infection.Evaluating Adult Cystic Fibrosis Care in BC: Disparities in Access to a Multidisciplinary Treatment Centre.Clearance of initial mucoid Pseudomonas aeruginosa in patients with cystic fibrosis.
P2860
Q24678466-7DABAACB-C02B-43D5-8177-4C1D92B4A333Q26470661-422D1D94-6F41-41F4-BCBC-32F3F9DC92D9Q26999299-8030E0C1-7AE4-4AC9-8431-80FC1DBB4742Q27021270-D22B63E6-1663-4F3C-ACE7-E5D0AA5151E5Q28077482-3FC26C83-6340-4BAF-AEC2-FE5A56A5CAF9Q28282739-7F7AC734-5705-4379-8F22-946D7C43CAF1Q28299966-F113A850-B439-4FDB-B011-99E551821095Q28492672-EE4E7C0D-4C26-4E5E-ADE3-E56D48629CC1Q29346778-62093E56-547F-4952-AF2E-CED6692D1D56Q30412485-E980A702-DDCF-43C5-9E2E-6A91CFAC68C4Q31140261-921AF9E9-B36C-47A8-8EA0-C95DD8BB4A46Q33559774-E6B88E23-2AE1-408F-B9C3-5B3A14C3912BQ33697276-707D5179-7117-44FA-BDBF-218F94614A43Q33713275-3EAEE5A5-4791-4585-9A19-27A8CD4E7734Q33862073-ACA7DE46-C2D6-48D4-9B3E-71C24590BD25Q34051927-57735F88-79D5-4DC4-89FC-D74CF5C1BBA7Q34115440-6D132089-5263-4860-AA23-507C2ED11091Q34134628-2D377C9D-E73D-46BE-A08A-AB2E921B5E39Q34180770-7567755F-EAE4-499A-8A7B-7CAE7A935A45Q34297656-E631EF7E-47DE-453D-8500-89C74EB525CAQ34757004-12E17B5A-1B40-4EAB-A16F-15A7382B571AQ34776102-84ADE325-A222-4F59-9685-44BA01F45631Q34795807-E79D345A-24F7-4608-88B1-2E72929CA547Q35005118-D68B98F8-89C8-4E86-B558-4654567108B7Q35006748-5D48BBBB-BCA0-4BB1-992D-5919FC694F54Q35060166-36B43D01-DED0-4718-91F0-66A674C8BCC7Q35260690-C086D4DD-5DA6-4AC7-8D97-FCF330DA32C5Q35800789-3A8DAA49-08FD-40F3-BE1B-3B866138A844Q35827006-44FD0678-F5B8-41D7-9A93-468B886E3DF9Q35878860-EF694049-EAC3-4467-90CE-0B8C20F6A52EQ36301225-20918212-E32A-487D-98D3-25EF9D1EF627Q36394592-B13528C8-CF72-40EF-AA60-8CB6E02C3A9EQ36448826-36C31479-78D1-46EB-874B-B2D1EE1A57A4Q36670892-92682E4D-455B-42BC-9409-0E2AEBE35E9DQ36670907-633E32CF-35B8-487A-AC40-7DF1E6AB27B2Q36673569-F30ACCF0-8A00-4AFF-AE64-F0DDF3C418B1Q36677316-BAC697D8-BADA-4E66-A34D-C79B22AD2558Q36895659-81084644-34CA-414C-872F-F9F4588E4063Q36996788-76406C58-8C8E-4DE0-B991-A7AE640FD7CEQ36999096-24D698AC-E2EF-4738-B549-22506FA3B5BE
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Eradication of early Pseudomonas aeruginosa infection.
@ast
Eradication of early Pseudomonas aeruginosa infection.
@en
type
label
Eradication of early Pseudomonas aeruginosa infection.
@ast
Eradication of early Pseudomonas aeruginosa infection.
@en
prefLabel
Eradication of early Pseudomonas aeruginosa infection.
@ast
Eradication of early Pseudomonas aeruginosa infection.
@en
P2093
P1476
Eradication of early Pseudomonas aeruginosa infection.
@en
P2093
Frederiksen B
Pressler T
P356
10.1016/J.JCF.2005.05.018
P478
P577
2005-08-01T00:00:00Z